At the end of culture with serum, C-28/I2 and T/C-28a2 chondrocytes were changed to serum-free medium for 2 hours, cells were incubated alone or with a range of concentrations (10−11 M, 10−9 M and 10−7 M) of letrozole (Femara; Novartis Oncology, Nuremberg, Germany) during the two serum-free days (days 6 and 7 or days 8 and 9, respectively). For this purpose, stock solutions of 10−1 M letrozole (EtOH-soluble) were prepared and dissolved stepwise with distilled H2O (EMD Millipore, Billerica, MA, USA). All experiments were performed in triplicate, and controls were incubated with water instead of the aromatase inhibitor letrozole.
Femara
Manufactured by Novartis
Sourced in Switzerland, Germany
Femara is a laboratory equipment product manufactured by Novartis. It is designed to perform various analytical and measurement tasks in research and development settings. The core function of Femara is to provide accurate and reliable data for scientific investigations, without any interpretation or extrapolation on its intended use.
Automatically generated - may contain errors
Lab products found in correlation
Letrozole, by Novartis (2 mentions)
Aromasin, by Pfizer (2 mentions)
Ovitrelle, by Merck Group (2 mentions)
Gonal f, by Merck Group (2 mentions)
Distilled h2o, by Merck Group (1 mentions)
Cetrotide, by Merck Group (1 mentions)
Letrozole, by Merck Group (1 mentions)
Glucophage, by Merck Group (1 mentions)
Quercetin, by Merck Group (1 mentions)
Pregnyl, by Organon (1 mentions)
Pharmorubicin rd, by Pfizer (1 mentions)
Docetaxel, by Sanofi (1 mentions)
Trastuzumab, by Roche (1 mentions)
Ovidrel, by Merck Group (1 mentions)
Ketamine, by Cristália (1 mentions)
Paraformaldehyde (pfa), by Merck Group (1 mentions)
18 protocols using femara
1
Chondrocyte Response to Letrozole
2
Polycystic Ovary Syndrome in Rodents
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The animals were divided equally (n = 18 each) into three groups: control, LTZ12 and CES12. The control group received normal saline solution by intraperitoneal injection (i.p) (2.5 ml/kg/day). In the LTZ12 group, ovulation was induced by LTZ which was diluted in normal saline solution (0.5 mg/kg/day, i.p, Femara; Novartis Pharma) on the first and second days of the menstrual cycle, which usually lasts for four days in rodents (Caligioni et al. 2009) . Then, human chorionic gonadotropin (hCG) (Pregnil; Schering-Plough, 100 UI/kg, i.p) was administrated on the third day of the cycle, while the fourth day remained free of any medications. This regimen was repeated for 12 cycles in the LTZ12 group. Likewise in the CES12 group, the same regimen of LTZ 12 stimulation was employed followed by a cessation of LTZ for a similar period. At the end of the experiment, salpingooophorectomy was performed by a professional obstetrician (Y.M.) in each animal under ketamine anaesthesia and strict sterile conditions.
3
Mitigating OHSS in High-Risk IVF Patients
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
281 consecutive high-risk patients received intra-venous fluid administration after the day of oocyte retrieval and were divided into a treatment group (n = 161) and control group (n = 120). The patients in the treatment group were informed of treatment options: letrozole group: (n = 43) received aromatase inhibitors letrozole tab (2.5 mg, bid, Femara; Novartis, Barcelona, Spain) per day for 5 consecutive days beginning on the day after oocyte retrieval. Mifepristone group (n = 51): received mifepristone tab (25 mg, bid; Zizhu Pharmaceuticals, Beijin, China) per day for 3 consecutive days beginning on the day after oocyte retrieval. GnRH-antagonist group (n = 39): received cetrotide (0.25 mg, qd, subcutaneous, Merck-Serono, Halle, Germany) per day for 5 consecutive days beginning on the day after oocyte retrieval. Three-drug combinations (Combinations) group (n = 28): took letrozole, mifepristone and cetrotide together at the same time. The control group (n = 120): received no special medication and was similar to the study group with regard to basal characteristics and ART stimulation parameters. In addition, 4454 patients under 38 years old planning to undergo their first IVF treatment as the non-high risk group were included and data on basal parameters were analyzed.
4
Exemestane vs Letrozole in Breast Cancer
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Patients were randomly assigned in a 1:1 ratio to treatment with exemestane (Aromasin; Pfizer, New York, NY), 25 mg orally daily, or letrozole (Femara; Novartis, Basel, Switzerland), 2.5 mg orally daily. Randomization was stratified by prior chemotherapy, prior tamoxifen, and bisphosphonate use. At baseline and after 1, 3, 6, 12, and 24 months, patients were clinically evaluated and completed PRO questionnaires (see next section). Blood samples were collected at baseline and after 3 months of therapy for evaluation of estrogen metabolites and pharmacokinetics (PK).
5
Randomized Comparison of Exemestane and Letrozole
6
Feather Dimorphism Response to Hormone Therapy
7
Letrozole Effect on Wistar Rats
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Sexually mature 3-month-old male Wistar rats were maintained under standard conditions of lighting (12L:12D) and nutrition. The animals were randomly divided into control and experimental groups (6 rats per group). Rats in the experimental group received per os letrozole (Femara®; Novartis Pharma, Nuremberg, Germany), a non-steroidal inhibitor of P450arom, at a dose of 1 mg/kg b.w./day for 6 months, as described in detail elsewhere [25 (link)]. Animals were then sacrificed under thiopental anesthesia (120 mg/kg b.w., i.p., Biochemie GmbH, Vienna, Austria). The experiment was conducted in full accordance with Polish law and with the approval of the Ethics Committee of Pomeranian Medical University, Szczecin.
8
Letrozole-Induced PCOS Management in Rats
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
In this experiment, female rats showing normal estrous cycle were selected and randomly divided into four groups (n = 6-8); the first group served as a control and was given 0.5% aqueous solution of Carboxymethylcellulose (2 mg/kg). The second group was PCOS positive group, administered with letrozole (Femara@, Novartis, Pakistan) at the concentration of 1 mg/kg dissolved in 0.5% CMC. The third group was given with letrozole (1 mg/kg dissolved in 0.5% CMC) and metformin (2 mg/100 g body weight) which is a commercially available drug (Glucophage purchased from Merck Serono, Quetta, Pakistan) for the treatment of PCOS. Fourth group was co-treated with letrozole (1 mg/kg dissolved in 0.5% CMC) and quercetin (30 mg/kg) (Q4951 Sigma). Body weight of all groups was recorded on every 5th day. All the animals were sacrificed by decapitation on the 22nd day of treatment.
9
Letrozole vs. Placebo for Breast Cancer
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Patients assigned by randomization to ARM1 (experimental arm) receive letrozole 2.5 mg (Femara®, Novartis) and patients assigned to ARM2 (control arm) will receive placebo (Novartis). The start is within 14 days after randomization from initial visit (M0), and orally taken once daily for a maximal total duration of 5 years or until symptomatic relapse, or other discontinuation reasons.
The tablet can be taken with or without food and should be swallowed whole with a glass of water or another liquid.
Letrozole or Placebo will be dispensed by the study nurse to the patient during her consultation at the center. The patient will receive 3-monthly supply of the experimental drug (after 2 years. 6-monthly supply). The study visits are scheduled according to the usual routine visits during the active study period.
The tablet can be taken with or without food and should be swallowed whole with a glass of water or another liquid.
Letrozole or Placebo will be dispensed by the study nurse to the patient during her consultation at the center. The patient will receive 3-monthly supply of the experimental drug (after 2 years. 6-monthly supply). The study visits are scheduled according to the usual routine visits during the active study period.
10
Letrozole Timing for Ovulation Induction
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
At the time of the first ultrasound examination, women were assigned to 1 of 4 experimental groups in a randomized, complete block design using a random number generator by HCMA. Women in the respective groups were given a single 20 mg oral dose of letrozole (Femara, Novartis Pharmaceuticals Canada, Inc., Dorval, Quebec) when the largest ovarian follicle after menses was first detected at a diameter of 1) 12 mm (n = 10; peri-selection group), 2) 18 mm (n = 10; pre-ovulatory group), or 3) within 24 h after ovulation (n = 10; post-ovulation group), or 4) were given no treatment (n = 11; control group).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!